Document_And_Entity_Informatio
Document And Entity Information (USD $) | 12 Months Ended | ||
Dec. 31, 2014 | Feb. 13, 2015 | Jun. 30, 2014 | |
Document and Entity Information [Abstract] | |||
Entity Registrant Name | Medizone International Inc | ||
Document Type | 10-K | ||
Current Fiscal Year End Date | -19 | ||
Entity Common Stock, Shares Outstanding | 346,334,068 | ||
Entity Public Float | $63,760,975 | ||
Amendment Flag | FALSE | ||
Entity Central Index Key | 753772 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Well-known Seasoned Issuer | No | ||
Document Period End Date | 31-Dec-14 | ||
Document Fiscal Year Focus | 2014 | ||
Document Fiscal Period Focus | FY |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Current assets: | ||
Cash | $140,496 | $81,856 |
Inventory | 265,234 | 265,234 |
Prepaid expenses | 60,705 | 33,085 |
Total current assets | 466,435 | 380,175 |
Property and equipment, net | 830 | 1,616 |
Other assets: | ||
Trademark and patents, net | 208,073 | 219,563 |
Lease deposit | 4,272 | 4,272 |
Total other assets | 212,345 | 223,835 |
Total assets | 679,610 | 605,626 |
Current liabilities: | ||
Accounts payable | 470,147 | 477,563 |
Accounts payable – related parties | 233,109 | 234,677 |
Accrued expenses | 516,434 | 522,179 |
Accrued expenses – related parties | 1,928,659 | 1,928,659 |
Customer deposits | 30,000 | 30,000 |
Other payables (Note 5) | 224,852 | 224,852 |
Notes payable | 298,241 | 295,496 |
Total current liabilities | 3,701,442 | 3,713,426 |
Commitments and contingencies (Notes 5 and 10) | ||
Stockholders’ deficit: | ||
Preferred stock, 50,000,000 shares of $0.00001 par value authorized; no shares issued or outstanding | 0 | 0 |
Common stock, 395,000,000 shares of $0.001 par value authorized; 346,034,068 and 322,055,496 shares issued and outstanding, respectively | 346,034 | 322,055 |
Additional paid-in capital | 30,052,656 | 28,018,398 |
Accumulated other comprehensive loss | -58,098 | -26,269 |
Accumulated deficit | -33,362,424 | -31,421,984 |
Total stockholders’ deficit | -3,021,832 | -3,107,800 |
Total liabilities and stockholders’ deficit | $679,610 | $605,626 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parentheticals) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Preferred stock, shares authorized | 50,000,000 | 50,000,000 |
Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, shares authorized | 395,000,000 | 395,000,000 |
Common stock, par value (in Dollars per share) | $0.00 | $0.00 |
Common stock, shares issued | 346,034,068 | 322,055,496 |
Common stock, shares outstanding | 346,034,068 | 322,055,496 |
Consolidated_Statements_of_Com
Consolidated Statements of Comprehensive Loss (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Revenues | $0 | $379,554 |
Operating expenses: | ||
Cost of revenues | 0 | 239,410 |
General and administrative | 1,445,049 | 1,125,681 |
Research and development | 420,945 | 278,280 |
Depreciation and amortization | 49,270 | 47,933 |
Total operating expenses | 1,915,264 | 1,691,304 |
Loss from operations | -1,915,264 | -1,311,750 |
Interest expense | -25,176 | -25,242 |
Net loss | -1,940,440 | -1,336,992 |
Other comprehensive loss: | ||
Loss on foreign currency translation | -31,829 | -1,825 |
Total comprehensive loss | ($1,972,269) | ($1,338,817) |
Basic and diluted net loss per common share (in Dollars per share) | ($0.01) | $0 |
Weighted average number of common shares outstanding (in Shares) | 335,658,604 | 307,880,349 |
Consolidated_Statements_of_Sto
Consolidated Statements of Stockholders' Equity (Deficit) (USD $) | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Retained Earnings [Member] | Total |
Balance at Dec. 31, 2012 | $288,771 | $26,506,566 | ($24,444) | ($30,084,992) | ($3,314,099) |
Balance (in Shares) at Dec. 31, 2012 | 288,771,227 | ||||
Common stock issued for cash | 33,284 | 1,379,966 | 1,413,250 | ||
Common stock issued for cash (in Shares) | 33,284,269 | ||||
Stock-based compensation | 131,866 | 131,866 | |||
Loss on foreign currency translation | -1,825 | -1,825 | |||
Net loss | -1,336,992 | -1,336,992 | |||
Balance at Dec. 31, 2013 | 322,055 | 28,018,398 | -26,269 | -31,421,984 | -3,107,800 |
Balance (in Shares) at Dec. 31, 2013 | 322,055,496 | 322,055,496 | |||
Common stock issued for cash | 23,979 | 1,580,271 | 1,604,250 | ||
Common stock issued for cash (in Shares) | 23,978,572 | 23,978,572 | |||
Stock-based compensation | 453,987 | 453,987 | |||
Loss on foreign currency translation | -31,829 | -31,829 | |||
Net loss | -1,940,440 | -1,940,440 | |||
Balance at Dec. 31, 2014 | $346,034 | $30,052,656 | ($58,098) | ($33,362,424) | ($3,021,832) |
Balance (in Shares) at Dec. 31, 2014 | 346,034,068 | 346,034,068 |
Consolidated_Statements_of_Sto1
Consolidated Statements of Stockholders' Equity (Deficit) (Parentheticals) (Common Stock [Member], USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Minimum [Member] | ||
Common stock issued for cash, per share | $0.05 | $0.03 |
Maximum [Member] | ||
Common stock issued for cash, per share | $0.09 | $0.06 |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Cash Flows From Operating Activities: | ||
Net loss | ($1,940,440) | ($1,336,992) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 49,270 | 47,813 |
Stock-based compensation | 453,987 | 131,866 |
Changes in operating assets and liabilities: | ||
Inventory | 0 | -219,686 |
Prepaid expenses | 37,594 | 148,245 |
Customer deposits | 0 | -4,554 |
Accounts payable and accounts payable – related parties | -8,986 | 23,783 |
Accrued expenses and accrued expenses – related parties | -5,745 | -11,936 |
Net Cash Used in Operating Activities | -1,414,320 | -1,221,461 |
Cash Flows From Investing Activities: | ||
Purchases of trademark and patents | -36,992 | -54,538 |
Net Cash Used in Investing Activities | -36,992 | -54,538 |
Cash Flows From Financing Activities: | ||
Principal payments on notes payable | -62,469 | -66,026 |
Issuance of common stock for cash | 1,604,250 | 1,413,250 |
Net Cash Provided by Financing Activities | 1,541,781 | 1,347,224 |
Effects of foreign currency exchanges rates | -31,829 | -1,825 |
Net Increase in Cash | 58,640 | 69,400 |
Cash as of Beginning of the Year | 81,856 | 12,456 |
Cash as of End of the Year | 140,496 | 81,856 |
Supplemental Cash Flow Information: | ||
Cash paid for interest | 1,520 | 1,587 |
Non-Cash Financing Activities: | ||
Financing of insurance premiums | $65,214 | $62,905 |
NOTE_1_ORGANIZATION_AND_SUMMAR
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Accounting Policies [Abstract] | |||||||||
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] | NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | ||||||||
a. Organization | |||||||||
The consolidated financial statements presented are those of Medizone International, Inc. (Medizone) and its wholly owned subsidiary, Medizone International, Inc. Delaware (Medizone-Delaware). The consolidated financial statements presented also include the accounts of the Canadian Foundation for Global Health (CFGH), a not-for-profit foundation based in Ottawa, Canada, considered to be a variable interest entity (VIE) as described below. Collectively, they are referred to herein as the “Company”. The Company is in the business of designing, manufacturing and selling a patented system using ozone in the disinfection of surgical and other medical treatment facilities and in other applications. | |||||||||
In late 2008, the Company assisted in the formation of CFGH, a not-for-profit foundation. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of its technology to as many in need as possible. | |||||||||
Accounting standards require a VIE to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the VIE’s expected residual returns as a result of holding variable interests, (ownership, contractual, or other financial interests) in the VIE. In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate the financial results of the VIE with it. The Company determined that CFGH met the requirements of a VIE, effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial position and results of operations of CFGH are consolidated with Medizone as of and for the years ended December 31, 2014 and 2013. | |||||||||
b. Business Activities | |||||||||
The Company’s objective is to pursue an initiative in the field of hospital disinfection. The Company has developed an ozone-based technology, specifically for the purpose of decontaminating and disinfecting hospital surgical suites, emergency rooms, and intensive care units. | |||||||||
c. Basic and Diluted Net Loss Per Common Share | |||||||||
The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the year as follows: | |||||||||
For the Years Ended | |||||||||
December 31, | |||||||||
2014 | 2013 | ||||||||
Numerator (net loss) | $ | (1,940,440 | ) | $ | (1,336,992 | ) | |||
Denominator (weighted average number of common shares outstanding) | 335,658,604 | 307,880,349 | |||||||
Basic and diluted net loss per common share | $ | (0.01 | ) | $ | (0.00 | ) | |||
Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the years presented. | |||||||||
d. Property and Equipment | |||||||||
Property and equipment are recorded at cost. Any major additions and improvements are capitalized. The cost and related accumulated depreciation of equipment retired or sold are removed from the accounts and any differences between the undepreciated amount and the proceeds from the sale are recorded as gain or loss on sale of property and equipment. Depreciation is computed using the straight-line method over a period of: (1) three years for computers and software, and (2) five years for office equipment and furniture. | |||||||||
e. Provision for Income Taxes | |||||||||
The Company estimates income taxes in each of the jurisdictions in which it operates. This process involves estimating the Company’s actual current income tax exposure together with assessing temporary differences resulting from differing treatment of items for income tax and financial reporting purposes. These temporary differences result in deferred income tax assets and liabilities, the net amount of which is included in the Company’s consolidated balance sheets. When appropriate, the Company records a valuation allowance to reduce its deferred income tax assets to the amount that the Company believes is more likely than not to be realized. Key assumptions used in estimating a valuation allowance include potential future taxable income, projected income tax rates, expiration dates of net operating loss and tax credit carry forwards, and ongoing prudent and feasible tax planning strategies. | |||||||||
As of December 31, 2014, the Company had net operating loss (“NOL”) carryforwards of approximately $10,267,000 that may be offset against future taxable income, if any, and expire in years 2015 through 2033. If substantial changes in the Company’s ownership should occur, there would also be an annual limitation of the amount of the NOL carryforwards which could be utilized. No tax benefit has been reported in the consolidated financial statements as, in the opinion of management, it is more likely than not that all of the deferred income tax assets will not be realized and the NOL carryforwards will expire unused. Deferred income tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. If the Company were to determine that it would be able to realize its deferred income tax assets in the future in excess of the net recorded amount, an adjustment to reduce the valuation allowance would increase net income or decrease net loss in the period such determination was made. | |||||||||
Interest and penalties associated with any underpayment of income taxes would be classified as income tax provision in the statements of comprehensive loss. | |||||||||
A company may adopt a policy of presenting taxes assessed by a governmental authority on revenue-producing transactions either on a gross basis or a net basis within revenues. The Company has elected to present revenues net of any tax collected. | |||||||||
Deferred income tax assets as of December 31, 2014 and 2013 comprised the following: | |||||||||
2014 | 2013 | ||||||||
Net operating loss carryforwards | $ | 4,090,400 | $ | 3,884,300 | |||||
Related-party accruals | 1,155,200 | 1,146,400 | |||||||
Valuation allowance | (5,245,600 | ) | (5,030,700 | ) | |||||
$ | - | $ | - | ||||||
The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income for the years ended December 31, 2014 and 2013 due to the following: | |||||||||
2014 | 2013 | ||||||||
Income tax benefit based on U.S. statutory rate of 34% | $ | (659,700 | ) | $ | (454,600 | ) | |||
Stock issued for expenses | 154,400 | 52,700 | |||||||
Other | 290,400 | 439,700 | |||||||
Change in valuation allowance | 214,900 | (37,800 | ) | ||||||
$ | - | $ | - | ||||||
e. Provision for Income Taxes (continued) | |||||||||
The Company had no uncertain income tax positions as of December 31, 2014 and 2013. | |||||||||
The Company files income tax returns in the U.S. federal and California jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local tax examinations for years before 2011. | |||||||||
f. Principles of Consolidation | |||||||||
The consolidated financial statements include the accounts of Medizone and its wholly owned inactive subsidiary, Medizone-Delaware. The consolidated financial statements presented also include the accounts of CFGH, a VIE. | |||||||||
All material intercompany accounts and transactions have been eliminated. | |||||||||
g. Estimates | |||||||||
The preparation of financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. | |||||||||
h. Advertising | |||||||||
The Company expenses the costs of advertising as incurred. | |||||||||
i. Stock Options | |||||||||
The Company records compensation expense in connection with the granting of stock options and their vesting periods based on their fair values. The Company estimates the fair values of stock option awards issued to employees at the grant date by using the Black-Scholes option-pricing model. For stock options issued to consultants and other non-employees, the Company estimates the related expense using the Black-Scholes option-pricing model. For stock options with a service condition, the expense is measured at the grant date and expensed over the vesting period. For stock options with a performance condition, the expense is measured when it is probable that the performance condition will be met, subsequently re-measured at each reporting date, and trued up upon the final completion of the performance condition. | |||||||||
j. Trademark and Patents | |||||||||
Trademark and patents are recorded at cost. Amortization is computed using the straight-line method over a period of seven years. The Company evaluates the recoverability of intangibles and reviews the amortization period on a continual basis. Several factors are used to evaluate intangibles, including management’s plans for future operations, recent operating results, and projected, undiscounted net cash flows. | |||||||||
k. Revenue Recognition Policy | |||||||||
The Company recognizes revenue when it ships its products, title and risk of loss passes to customers, payment from the customer is reasonably assured and the price is fixed or determinable. The Company records customer deposits that have not yet been earned as unearned revenue. | |||||||||
l. Inventory | |||||||||
The Company’s inventory consists of its AsepticSure® product and is valued on a specific identification basis. The Company purchases its inventory as a finished product from unrelated manufacturing companies. The Company determined that there was no obsolete or excess inventory as of December 31, 2014 or 2013. | |||||||||
m. Fair Value of Financial Instruments | |||||||||
The Company’s financial instruments consist of cash, accounts payable, and notes payable. The carrying amounts of cash and accounts payable approximate their fair values because of the short-term nature of these instruments. The carrying amounts of the notes payable approximate fair values as the individual borrowings bear interest at rates that approximate market interest rates for similar debt instruments. | |||||||||
n. Recent Accounting Pronouncements | |||||||||
In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all existing revenue recognition guidance under US GAAP. The core principle of ASU No. 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU No. 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing US GAAP. The standard is effective for annual reporting periods beginning after December 15, 2016, and interim periods therein. Early adoption is not permitted. The Company is currently assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity. | |||||||||
In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This standard sets forth management’s responsibility to evaluate, each reporting period, whether there is substantial doubt about the entity’s ability to continue as a going concern, and if so, to provide related footnote disclosures. The standard is for annual reporting periods beginning after December 15, 2016, and interim periods within annual periods ending after December 15, 2016. The Company is currently assessing the impact, if any, of implementing this guidance will have on the Company. | |||||||||
o. Concentration of Credit Risk | |||||||||
The Company maintains its cash in bank deposit accounts which cash, at times, exceeds federally insured limits. As of December 31, 2014 and 2013, the Company had no cash balances that exceeded federally insured limits. To date, the Company has not experienced a material loss or lack of access to its cash; however, no assurance can be provided that access to the Company’s cash will not be impacted by adverse conditions in the financial markets. | |||||||||
NOTE_2_PROPERTY_AND_EQUIPMENT
NOTE 2 - PROPERTY AND EQUIPMENT | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Property, Plant and Equipment [Abstract] | |||||||||
Property, Plant and Equipment Disclosure [Text Block] | NOTE 2 - PROPERTY AND EQUIPMENT | ||||||||
Property and equipment consist of the following as of December 31, 2014 and 2013: | |||||||||
2014 | 2013 | ||||||||
Computers and software | $ | 2,938 | $ | 2,938 | |||||
Furniture | 2,075 | 2,075 | |||||||
5,013 | 5,013 | ||||||||
Accumulated depreciation | (4,183 | ) | (3,397 | ) | |||||
Property and equipment, net | $ | 830 | $ | 1,616 | |||||
Depreciation expense for the years ended December 31, 2014 and 2013 was $787 and $4,203, respectively. | |||||||||
NOTE_3_TRADEMARK_AND_PATENTS
NOTE 3 - TRADEMARK AND PATENTS | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Disclosure Text Block [Abstract] | |||||||||
Intangible Assets Disclosure [Text Block] | NOTE 3 - TRADEMARK AND PATENTS | ||||||||
Trademark and patents consist of the following as of December 31, 2014 and 2013: | |||||||||
2014 | 2013 | ||||||||
Patent costs | $ | 362,956 | $ | 325,964 | |||||
Trademark | 770 | 770 | |||||||
363,726 | 326,734 | ||||||||
Accumulated amortization | (155,653 | ) | (107,171 | ) | |||||
Trademark and patents, net | $ | 208,073 | $ | 219,563 | |||||
Amortization expense for the years ended December 31, 2014 and 2013 was $48,483 and $43,730, respectively. The future amortization as of December 31, 2014 is as follows: 2015-$51,310; 2016-$51,109; 2017-$43,860; 2018-$31,280; 2019-$17,615; and thereafter-$12,899. | |||||||||
NOTE_4_ACCRUED_EXPENSES_AND_AC
NOTE 4 - ACCRUED EXPENSES AND ACCRUED EXPENSES - RELATED PARTIES | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Payables and Accruals [Abstract] | |||||||||
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | NOTE 4 - ACCRUED EXPENSES AND ACCRUED EXPENSES – RELATED PARTIES | ||||||||
Accrued expenses and accrued expenses – related parties consist of the following as of December 31, 2014 and 2013: | |||||||||
2014 | 2013 | ||||||||
Accrued payroll and consulting – related parties | $ | 1,812,106 | $ | 1,812,106 | |||||
Accrued interest | 502,269 | 478,613 | |||||||
Accrued payroll taxes – related parties | 116,553 | 116,553 | |||||||
Other accruals | 14,165 | 43,566 | |||||||
Total | $ | 2,445,093 | $ | 2,450,838 | |||||
Accrued expenses – related parties relate to accrued but unpaid payroll and consulting fees (and associated taxes) for certain of the Company’s employees and consultants who are also directors, officers or stockholders. | |||||||||
NOTE_5_COMMITMENTS_AND_CONTING
NOTE 5 - COMMITMENTS AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2014 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 5 - COMMITMENTS AND CONTINGENCIES |
Litigation | |
The Company is subject to certain claims and lawsuits arising in the normal course of business. In the opinion of management, uninsured losses, if any, resulting from the ultimate resolution of these matters will not have a material effect on the Company’s consolidated financial position, results of operations, or cash flows. | |
Rakas vs. Medizone International, Inc. - A former consultant brought this action against the Company claiming the Company had failed to pay consulting fees under a consulting agreement. In September 2001, the parties agreed to settle the matter for $25,000. The Company, however, did not have the funds to pay the settlement and the plaintiff moved the court to enter a default judgment in the amount of $143,000 in January 2002. On May 8, 2002, the court vacated the default judgment and requested that the Company post a bond of $25,000 to cover the settlement previously entered into by the parties. The Company has been unable to post the required bond amount as of the date of this report. Therefore, the Company has recorded, as part of accounts payable, the original default judgment in the amount of $143,000, plus fees totaling $21,308, as of December 31, 2014 and 2013. The Company intends to contest the judgment if and when it is able to do so in the future. | |
Other Payables | |
As of December 31, 2014 and 2013, the Company has recorded other payables totaling $224,852 related to certain past due payables for which the Company has not received invoices or demands for over 10 years. Although management of the Company does not believe that the amounts will be paid, the amounts have been recorded as other payables until such time as the Company is certain that no liability exists and until the statute of limitations has expired. | |
Operating Leases | |
The Company operates a certified laboratory located at Innovation Park, Queen’s University in Kingston, Ontario, Canada, which provides a primary research and development platform. The lease term is month to month with a monthly lease payment of $1,375 Canadian dollars (“CD”) plus the applicable goods and services tax (“GST”). Leases for a second laboratory space for full scale room testing and a storage unit are on a month to month basis with a monthly lease payment of CD$1,375 and CD$475, respectively, plus the applicable GST. | |
The Company has a corporate office lease with monthly payments of approximately $2,300 through December 31, 2015. | |
NOTE_6_EQUITY_TRANSACTIONS
NOTE 6 - EQUITY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2014 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 6 - EQUITY TRANSACTIONS |
Unless otherwise stated, the following equity transactions were with unrelated parties and the securities issued were restricted. There were no underwriters involved. | |
Common Stock for Cash – 2013 | |
During January, February, and March 2013, the Company sold an aggregate of 12,233,332 restricted shares of common stock to 12 accredited investors for cash proceeds totaling $367,000, or $0.03 per share. | |
During April and May 2013, the Company sold 3,794,444 restricted shares of common stock to six accredited investors for cash proceeds totaling $170,750, or $0.045 per share. | |
During May and June 2013, the Company sold 5,863,636 restricted shares of common stock to 12 accredited investors for cash proceeds totaling $322,500, or $0.055 per share. | |
During August and September 2013, the Company sold 5,000,000 restricted shares of common stock to eight accredited investors for cash proceeds totaling $300,000, or $0.06 per share. | |
During October 2013, the Company sold 1,950,000 restricted shares of common stock to five accredited investors for cash proceeds totaling $97,500, or $0.05 per share. | |
During December 2013, the Company sold 4,442,857 restricted shares of common stock to six accredited investors for cash proceeds totaling $155,500, or $0.035 per share. | |
Common Stock for Cash – 2014 | |
During January, February and March 2014, the Company sold an aggregate of 9,000,000 restricted shares of common stock to five accredited investors for cash proceeds totaling $450,000, or $0.05 per share. | |
During March 2014, the Company sold an aggregate of 7,050,000 restricted shares of common stock to 16 accredited investors for cash proceeds totaling $599,250, or $0.085 per share. | |
During September 2014, the Company sold an aggregate of 2,471,429 restricted shares of common stock to five accredited investors for cash proceeds totaling $173,000, or $0.07 per share. | |
During November 2014, the Company sold 2,907,143 restricted shares of common stock to five accredited investors for cash proceeds totaling $203,500, or $0.07 per share. | |
During December 2014, the Company sold 2,550,000 restricted shares of common stock to an accredited investor for cash proceeds totaling $178,500, or $0.07 per share. | |
Recapitalization | |
The Company’s amended Articles of Incorporation (“AOI”) include a class of preferred stock, par value $0.00001, with authorized shares of 50,000,000. To date, no shares of preferred stock have been issued. The rights and preferences of the authorized preferred shares will be determined by the Company’s Board of Directors. | |
The amended AOI authorize 395,000,000 shares of common stock, par value $0.001. | |
NOTE_7_COMMON_STOCK_OPTIONS
NOTE 7 - COMMON STOCK OPTIONS | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Disclosure Text Block Supplement [Abstract] | |||||||||
Shareholders' Equity and Share-based Payments [Text Block] | NOTE 7 - COMMON STOCK OPTIONS | ||||||||
On August 26, 2009, the Company granted options for the purchase of 1,500,000 shares of common stock to an outside consultant for services rendered, with an exercise price of $0.10 per share. The options are exercisable for up to five years and have vesting provisions as follows: (i) options for 500,000 shares vested immediately on the date of grant, (ii) options for 500,000 shares vested in September 2012, the date certified by the Company as the date its hospital disinfection program completed its beta-testing, and (iii) the remaining options for 500,000 shares were to vest on the date certified by the Company as the date that its disinfection process has been commercialized and a minimum of 50 units or devices have been sold to third parties. During the year ended December 31, 2014, all these options expired and were cancelled. | |||||||||
In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to a consultant for distribution channel related services to be performed. Options totaling 550,000 shares have vested as of December 31, 2014, and the remaining options will vest on the date certified by the Company as the date that the other milestones are achieved. The options have an exercise price of $0.17 per share, and are exercisable for up to five years. The Company recognized $69,300 of expense during the year ended December 31, 2013. The Company will measure and begin recognizing the remaining expense when the achievement of the required milestones becomes probable. | |||||||||
In May 2012, the Company granted options for the purchase of 1,000,000 shares of common stock to a consultant for medical consulting support services already performed (vested immediately on the grant date) and to be performed in the future, which do not vest until completion of certain milestones. The options have an exercise price of $0.17 per share, and are exercisable for up to five years. The grant date fair value of these options was $149,460. The Company recognized $49,322 of expense during the year ended December 31, 2013. As of December 31, 2013, all of the milestones were achieved and all of the shares were vested. | |||||||||
In August 2013, the Company granted options for the purchase of 250,000 shares of common stock to a consultant. These options are exercisable at $0.10 per share for five years from the date of grant with 50,000 options vesting immediately and the other 200,000 options vesting upon the achievement of certain milestones. The Company recognized $4,415 of expense during the year ended December 31, 2013. The Company will measure and begin recognizing the remaining expense when the achievement of the required milestones becomes probable. | |||||||||
In August 2013, the Company granted options for the purchase of 100,000 shares of common stock to an employee for services performed. The options vested upon grant, have an exercise price of $0.10 per share, and are exercisable for up to five years. The value of the options was $8,829 which the Company recognized as expense during the year ended December 31, 2013. | |||||||||
On February 26, 2014, the Company granted to a new director options for the purchase of 2,000,000 shares of common stock, with an exercise price of $0.1095 per share. Of these options, 1,000,000 will vest on February 26, 2015 and the remaining 1,000,000 options will vest upon the successful achievement of certain milestones. Unvested options vest immediately in the event of a change in control of the Company. The options are exercisable for five years. The Company recognized $80,076 of expense during the year ended December 31, 2014, with $16,016 to be recognized over the remaining vesting period in connection with those options that vest on February 26, 2015. Also, the Company will measure and begin recognizing the remaining expense when the achievement of the required milestones becomes probable. | |||||||||
On February 26, 2014, the Company granted options to six consultants and service providers for the purchase of a total of 250,000 shares of common stock at an exercise price of $0.1095 per share. Options for 200,000 shares vested immediately upon grant and options for the remaining 50,000 shares vested on January 9, 2015. The options are exercisable for five years. The grant date fair value of these options was $24,023. The Company recognized expense of $23,223 during the year ended December 31, 2014 and the remaining expense of $800 will be recognized over the remaining vesting period in connection with those options that vested on January 9, 2015. | |||||||||
On April 30, 2014, the Company granted options for the purchase of a total of 1,350,000 shares of common stock for services rendered, as follows: 250,000 shares to each of four directors of the Company, 100,000 shares to each of two consultants, and 75,000 shares each to a consultant and an employee of the Company. All options vested upon grant, have an exercise price of $0.163 per share, and are exercisable for up to five years. The total value of these options at the date of grant was $193,234, which the Company recognized as an expense during the year ended December 31, 2014. | |||||||||
On May 6, 2014, the Company granted options to a consultant for the purchase of 100,000 shares of common stock at an exercise price of $0.19 per share. Options for 50,000 shares vested immediately upon grant and options for the remaining 50,000 shares will vest when certain required milestones are achieved. The options are exercisable for five years. The Company recognized expense of $8,342 year ended December 31, 2014 and the remaining expense will be measured and begin to be recognized when the achievement of the required milestones becomes probable. | |||||||||
On August 15, 2014, the Company granted options to a consultant for the purchase of 75,000 shares of common stock at an exercise price of $0.13 per share. The shares will vest when certain required milestones are achieved. The options are exercisable for five years. The Company will measure and begin recognizing an expense when the achievement of the required milestones becomes probable. | |||||||||
On August 15, 2014, the Company granted options for services rendered to a director of the Company for the purchase of 1,000,000 shares of common stock at an exercise price of $0.13 per share. These options vested immediately upon grant. The Company recognized expense of $114,069 during the year ended December 31, 2014, which was the grant date fair value of these options. | |||||||||
On October 7, 2014, the Company granted to a new board member options for the purchase of 1,000,000 shares of common stock, with an exercise price of $0.16 per share. These options will vest on October 7, 2015. Unvested options vest immediately in the event of a change in control of the Company. The options are exercisable for five years. The grant date fair value of the options was $140,178. The Company recognized $35,044 of expense during the year ended December 31, 2014, with $105,133 to be recognized over the remaining vesting period in connection with these options that vest on October 7, 2015. | |||||||||
On December 4, 2014, the Company granted options to four consultants for the purchase of 140,000 shares of common stock at an exercise price of $0.11 per share. The shares will vest when certain required milestones are achieved. The options are exercisable for five years. The Company will measure and begin recognizing an expense when the achievement of the required milestones becomes probable. | |||||||||
The options granted in April, May, August, October and December 2014, were granted under the Company’s new 2014 Equity Compensation Plan (the “2014 Plan”) adopted on April 30, 2014 by the Board of Directors. The Company filed a registration statement on Form S-8 on July 17, 2014, to register 6,000,000 shares of common stock that may be issued under awards made pursuant to the 2014 Plan. | |||||||||
The Company estimates the fair value of each stock award by using the Black-Scholes option-pricing model, which model requires the use of exercise behavior data and the use of a number of assumptions including expected volatility of the Company’s stock price, the weighted average risk-free interest rate, and the weighted average expected life of the options. Because the Company does not pay dividends, the dividend rate variable in the Black-Scholes option-pricing model is zero. Expense of $453,987 and $131,866 was recorded for the years ended December 31, 2014 and 2013, respectively. Excluding options whose performance condition is not yet deemed probable, as of December 31, 2014 the Company had various unvested outstanding options with related unrecognized expense of $121,949. The Company will recognize this expense as the options vest over their remaining useful lives which range from 50 to 58 months. | |||||||||
The Company estimated the fair value of the stock options at the date of the grant, based on the following weighted average assumptions: | |||||||||
Risk-free interest rate | 1.5 | % | to | 1.69 | % | ||||
Expected life | 5 years | ||||||||
Expected volatility | 135.74 | % | to | 136.44 | % | ||||
Dividend yield | 0 | % | |||||||
A summary of the status of the Company’s outstanding options as of December 31, 2014 and changes during the year then ended is presented below: | |||||||||
Shares | Weighted Average | ||||||||
Exercise Price | |||||||||
Outstanding, January 1, 2014 | 15,150,000 | $ | 0.19 | ||||||
Granted | 5,915,000 | 0.14 | |||||||
Expired/Canceled | (2,500,000 | ) | 0.1 | ||||||
Outstanding, December 31, 2014 | 18,565,000 | 0.18 | |||||||
Exercisable | 14,600,000 | 0.2 | |||||||
NOTE_8_ACCOUNTS_PAYABLE_RELATE
NOTE 8 - ACCOUNTS PAYABLE - RELATED PARTIES | 12 Months Ended |
Dec. 31, 2014 | |
Related Party Transactions [Abstract] | |
Related Party Transactions Disclosure [Text Block] | NOTE 8 - ACCOUNTS PAYABLE – RELATED PARTIES |
As of December 31, 2014 and 2013, the Company owed $233,109 and $234,677, respectively, to certain consultants for services. These consultants are stockholders of the Company and are related parties. | |
NOTE_9_NOTES_PAYABLE
NOTE 9 - NOTES PAYABLE | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Debt Disclosure [Abstract] | |||||||||
Debt Disclosure [Text Block] | NOTE 9 - NOTES PAYABLE | ||||||||
Notes payable consist of the following as of December 31, 2014 and 2013: | |||||||||
2014 | 2013 | ||||||||
Unsecured notes payable to former directors and a family member of a former director, due at various dates in 1995, 1996 and 1997 (principal and accrued interest as of December 31, 2014), interest at 8% per annum. The Company has the right to repay the loans with restricted stock at $0.10 per share if alternative financings do not occur. These notes payable are in default. | $ | 182,676 | $ | 182,676 | |||||
Unsecured notes payable to 10 stockholders, due on demand, interest at 10% per annum (principal and accrued interest, as of December 31, 2014). The Company is obligated to accept the principal rate at face value plus accrued interest as partial payment for shares the lenders may purchase from the Company upon exercise of the lenders’ option to acquire shares from the Company. | 60,815 | 60,815 | |||||||
Unsecured notes payable to directors totaling $28,000 and a note payable to a third party in the amount of $9,000, due on April 22, 1995 (principal and accrued interest as of December 31, 2014), interest at 8% per annum. Each lender has the right to convert any portion of the principal and interest into common stock at a price per share equal to the price per share under a prior private placement transaction. These notes payable are in default. | 37,000 | 37,000 | |||||||
Unsecured notes payable to a financing company, payable in nine monthly installments, interest ranging from 4.00% to 5.68% per annum, mature in April, July and November 2015. | 17,750 | 15,005 | |||||||
Total notes payable (all current) | $ | 298,241 | $ | 295,496 | |||||
The notes payable balances as of December 31, 2014 have been classified as current as each note payable is due on or before December 31, 2015. | |||||||||
NOTE_10_GOING_CONCERN
NOTE 10 - GOING CONCERN | 12 Months Ended |
Dec. 31, 2014 | |
Going Concern Disclosure [Abstract] | |
Going Concern Disclosure [Text Block] | NOTE 10 - GOING CONCERN |
The Company’s consolidated financial statements are prepared in accordance with U.S. GAAP which assumes an entity is a going concern and contemplates the realization of assets and the settlement of liabilities in the normal course of business. The Company has incurred significant recurring losses from its inception through December 31, 2014, which have resulted in an accumulated deficit of $33,362,424 as of December 31, 2014. The Company has minimal cash, has a working capital deficit of $3,235,007, and a total stockholders’ deficit of $3,021,832 as of December 31, 2014. The Company has relied almost exclusively on debt and equity financing to sustain its operations. Accordingly, there is substantial doubt about its ability to continue as a going concern. | |
Continuation of the Company as a going concern is dependent upon obtaining additional capital and ultimately, upon the Company attaining profitable operations. The Company will require a substantial amount of additional funds to complete the continued development of its products, product manufacturing, and to fund additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the necessary additional funding, it will most likely be forced to substantially reduce or cease operations. | |
The Company believes that it will need approximately $1,500,000 during the next 12 months for continued production manufacturing and related activities, research, development, marketing activities, as well as for general corporate purposes. | |
During 2014, the Company raised a total of $1,604,250 through the sale of 23,978,572 shares of common stock at prices ranging from $0.05 to $0.085 per share, which funds have been used to keep the Company current in its public reporting obligations and to pay certain other corporate obligations including the costs of development for its hospital disinfection system. | |
Subsequent to December 31, 2014, through the date of this report, the Company raised a total of $21,000 through the sale of 300,000 shares of common stock at a price of $0.07 per share. The Company believes it can raise additional funds from certain investors who have purchased shares from 2009 through 2014, although there is no assurance that these investors will purchase additional shares. | |
The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. | |
NOTE_11_CUSTOMER_DEPOSITS
NOTE 11 - CUSTOMER DEPOSITS | 12 Months Ended |
Dec. 31, 2014 | |
Deferred Revenue Disclosure [Abstract] | |
Deferred Revenue Disclosure [Text Block] | NOTE 11 – CUSTOMER DEPOSITS |
As of December 31, 2014 and 2013, the Company received purchase orders and related customer deposits totaling $30,000 to purchase the AsepticSure® hospital disinfection systems and related equipment. As of December 31, 2014 and 2013, these customer deposits were reflected as current liabilities. | |
NOTE_12_SUBSEQUENT_EVENTS
NOTE 12 - SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2014 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | NOTE 12 – SUBSEQUENT EVENTS |
The Company has evaluated subsequent events through the filing date of this Annual Report on Form 10-K and has determined it appropriate to disclose the following event. | |
During 2015, the Company sold an aggregate of 300,000 restricted shares of common stock to an accredited investors for cash proceeds of $21,000, or $0.07 per share. | |
Accounting_Policies_by_Policy_
Accounting Policies, by Policy (Policies) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Accounting Policies [Abstract] | |||||||||
Basis of Accounting, Policy [Policy Text Block] | a. Organization | ||||||||
The consolidated financial statements presented are those of Medizone International, Inc. (Medizone) and its wholly owned subsidiary, Medizone International, Inc. Delaware (Medizone-Delaware). The consolidated financial statements presented also include the accounts of the Canadian Foundation for Global Health (CFGH), a not-for-profit foundation based in Ottawa, Canada, considered to be a variable interest entity (VIE) as described below. Collectively, they are referred to herein as the “Company”. The Company is in the business of designing, manufacturing and selling a patented system using ozone in the disinfection of surgical and other medical treatment facilities and in other applications. | |||||||||
In late 2008, the Company assisted in the formation of CFGH, a not-for-profit foundation. The Company helped establish CFGH for two primary purposes: (1) to establish an independent not-for-profit foundation intended to have a continuing working relationship with the Company for research purposes that is best positioned to attract the finest scientific, medical and academic professionals possible to work on projects deemed to be of social benefit; and (2) to provide a means for the Company to use a tiered pricing structure for services and products in emerging economies and extend the reach of its technology to as many in need as possible. | |||||||||
Accounting standards require a VIE to be consolidated by a company if that company absorbs a majority of the VIE’s expected losses and/or receives a majority of the VIE’s expected residual returns as a result of holding variable interests, (ownership, contractual, or other financial interests) in the VIE. In addition, a legal entity is considered to be a VIE, if it does not have sufficient equity at risk to finance its own activities without relying on financial support from other parties. If the legal entity is a VIE, then the reporting entity determined to be the primary beneficiary of the VIE must consolidate the financial results of the VIE with it. The Company determined that CFGH met the requirements of a VIE, effective upon the first advance to CFGH on February 12, 2009. Accordingly, the financial position and results of operations of CFGH are consolidated with Medizone as of and for the years ended December 31, 2014 and 2013. | |||||||||
b. Business Activities | |||||||||
The Company’s objective is to pursue an initiative in the field of hospital disinfection. The Company has developed an ozone-based technology, specifically for the purpose of decontaminating and disinfecting hospital surgical suites, emergency rooms, and intensive care units. | |||||||||
Earnings Per Share, Policy [Policy Text Block] | c. Basic and Diluted Net Loss Per Common Share | ||||||||
The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the year as follows: | |||||||||
For the Years Ended | |||||||||
December 31, | |||||||||
2014 | 2013 | ||||||||
Numerator (net loss) | $ | (1,940,440 | ) | $ | (1,336,992 | ) | |||
Denominator (weighted average number of common shares outstanding) | 335,658,604 | 307,880,349 | |||||||
Basic and diluted net loss per common share | $ | (0.01 | ) | $ | (0.00 | ) | |||
Common stock equivalents, consisting of options, have not been included in the calculation as their effect is antidilutive for the years presented. | |||||||||
Income Tax, Policy [Policy Text Block] | e. Provision for Income Taxes | ||||||||
The Company estimates income taxes in each of the jurisdictions in which it operates. This process involves estimating the Company’s actual current income tax exposure together with assessing temporary differences resulting from differing treatment of items for income tax and financial reporting purposes. These temporary differences result in deferred income tax assets and liabilities, the net amount of which is included in the Company’s consolidated balance sheets. When appropriate, the Company records a valuation allowance to reduce its deferred income tax assets to the amount that the Company believes is more likely than not to be realized. Key assumptions used in estimating a valuation allowance include potential future taxable income, projected income tax rates, expiration dates of net operating loss and tax credit carry forwards, and ongoing prudent and feasible tax planning strategies. | |||||||||
As of December 31, 2014, the Company had net operating loss (“NOL”) carryforwards of approximately $10,267,000 that may be offset against future taxable income, if any, and expire in years 2015 through 2033. If substantial changes in the Company’s ownership should occur, there would also be an annual limitation of the amount of the NOL carryforwards which could be utilized. No tax benefit has been reported in the consolidated financial statements as, in the opinion of management, it is more likely than not that all of the deferred income tax assets will not be realized and the NOL carryforwards will expire unused. Deferred income tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. If the Company were to determine that it would be able to realize its deferred income tax assets in the future in excess of the net recorded amount, an adjustment to reduce the valuation allowance would increase net income or decrease net loss in the period such determination was made. | |||||||||
Interest and penalties associated with any underpayment of income taxes would be classified as income tax provision in the statements of comprehensive loss. | |||||||||
A company may adopt a policy of presenting taxes assessed by a governmental authority on revenue-producing transactions either on a gross basis or a net basis within revenues. The Company has elected to present revenues net of any tax collected. | |||||||||
Deferred income tax assets as of December 31, 2014 and 2013 comprised the following: | |||||||||
2014 | 2013 | ||||||||
Net operating loss carryforwards | $ | 4,090,400 | $ | 3,884,300 | |||||
Related-party accruals | 1,155,200 | 1,146,400 | |||||||
Valuation allowance | (5,245,600 | ) | (5,030,700 | ) | |||||
$ | - | $ | - | ||||||
The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income for the years ended December 31, 2014 and 2013 due to the following: | |||||||||
2014 | 2013 | ||||||||
Income tax benefit based on U.S. statutory rate of 34% | $ | (659,700 | ) | $ | (454,600 | ) | |||
Stock issued for expenses | 154,400 | 52,700 | |||||||
Other | 290,400 | 439,700 | |||||||
Change in valuation allowance | 214,900 | (37,800 | ) | ||||||
$ | - | $ | - | ||||||
e. Provision for Income Taxes (continued) | |||||||||
The Company had no uncertain income tax positions as of December 31, 2014 and 2013. | |||||||||
The Company files income tax returns in the U.S. federal and California jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local tax examinations for years before 2011. | |||||||||
Property, Plant and Equipment, Policy [Policy Text Block] | d. Property and Equipment | ||||||||
Property and equipment are recorded at cost. Any major additions and improvements are capitalized. The cost and related accumulated depreciation of equipment retired or sold are removed from the accounts and any differences between the undepreciated amount and the proceeds from the sale are recorded as gain or loss on sale of property and equipment. Depreciation is computed using the straight-line method over a period of: (1) three years for computers and software, and (2) five years for office equipment and furniture. | |||||||||
Consolidation, Policy [Policy Text Block] | f. Principles of Consolidation | ||||||||
The consolidated financial statements include the accounts of Medizone and its wholly owned inactive subsidiary, Medizone-Delaware. The consolidated financial statements presented also include the accounts of CFGH, a VIE. | |||||||||
All material intercompany accounts and transactions have been eliminated. | |||||||||
Use of Estimates, Policy [Policy Text Block] | g. Estimates | ||||||||
The preparation of financial statements in conformity with U.S. generally accepted accounting principles (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. | |||||||||
Advertising Costs, Policy [Policy Text Block] | h. Advertising | ||||||||
The Company expenses the costs of advertising as incurred. | |||||||||
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | i. Stock Options | ||||||||
The Company records compensation expense in connection with the granting of stock options and their vesting periods based on their fair values. The Company estimates the fair values of stock option awards issued to employees at the grant date by using the Black-Scholes option-pricing model. For stock options issued to consultants and other non-employees, the Company estimates the related expense using the Black-Scholes option-pricing model. For stock options with a service condition, the expense is measured at the grant date and expensed over the vesting period. For stock options with a performance condition, the expense is measured when it is probable that the performance condition will be met, subsequently re-measured at each reporting date, and trued up upon the final completion of the performance condition. | |||||||||
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | j. Trademark and Patents | ||||||||
Trademark and patents are recorded at cost. Amortization is computed using the straight-line method over a period of seven years. The Company evaluates the recoverability of intangibles and reviews the amortization period on a continual basis. Several factors are used to evaluate intangibles, including management’s plans for future operations, recent operating results, and projected, undiscounted net cash flows. | |||||||||
Revenue Recognition, Policy [Policy Text Block] | k. Revenue Recognition Policy | ||||||||
The Company recognizes revenue when it ships its products, title and risk of loss passes to customers, payment from the customer is reasonably assured and the price is fixed or determinable. The Company records customer deposits that have not yet been earned as unearned revenue. | |||||||||
Inventory, Policy [Policy Text Block] | l. Inventory | ||||||||
The Company’s inventory consists of its AsepticSure® product and is valued on a specific identification basis. The Company purchases its inventory as a finished product from unrelated manufacturing companies. The Company determined that there was no obsolete or excess inventory as of December 31, 2014 or 2013. | |||||||||
Fair Value of Financial Instruments, Policy [Policy Text Block] | m. Fair Value of Financial Instruments | ||||||||
The Company’s financial instruments consist of cash, accounts payable, and notes payable. The carrying amounts of cash and accounts payable approximate their fair values because of the short-term nature of these instruments. The carrying amounts of the notes payable approximate fair values as the individual borrowings bear interest at rates that approximate market interest rates for similar debt instruments. | |||||||||
New Accounting Pronouncements, Policy [Policy Text Block] | n. Recent Accounting Pronouncements | ||||||||
In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which supersedes nearly all existing revenue recognition guidance under US GAAP. The core principle of ASU No. 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU No. 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing US GAAP. The standard is effective for annual reporting periods beginning after December 15, 2016, and interim periods therein. Early adoption is not permitted. The Company is currently assessing the impact, if any, of implementing this guidance on its consolidated financial position, results of operations and liquidity. | |||||||||
In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This standard sets forth management’s responsibility to evaluate, each reporting period, whether there is substantial doubt about the entity’s ability to continue as a going concern, and if so, to provide related footnote disclosures. The standard is for annual reporting periods beginning after December 15, 2016, and interim periods within annual periods ending after December 15, 2016. The Company is currently assessing the impact, if any, of implementing this guidance will have on the Company. | |||||||||
Concentration Risk, Credit Risk, Policy [Policy Text Block] | o. Concentration of Credit Risk | ||||||||
The Company maintains its cash in bank deposit accounts which cash, at times, exceeds federally insured limits. As of December 31, 2014 and 2013, the Company had no cash balances that exceeded federally insured limits. To date, the Company has not experienced a material loss or lack of access to its cash; however, no assurance can be provided that access to the Company’s cash will not be impacted by adverse conditions in the financial markets. |
NOTE_1_ORGANIZATION_AND_SUMMAR1
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Accounting Policies [Abstract] | |||||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | The computations of basic and diluted net loss per common share are based on the weighted average number of common shares outstanding during the year as follows: | ||||||||
For the Years Ended | |||||||||
December 31, | |||||||||
2014 | 2013 | ||||||||
Numerator (net loss) | $ | (1,940,440 | ) | $ | (1,336,992 | ) | |||
Denominator (weighted average number of common shares outstanding) | 335,658,604 | 307,880,349 | |||||||
Basic and diluted net loss per common share | $ | (0.01 | ) | $ | (0.00 | ) | |||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | Deferred income tax assets as of December 31, 2014 and 2013 comprised the following: | ||||||||
2014 | 2013 | ||||||||
Net operating loss carryforwards | $ | 4,090,400 | $ | 3,884,300 | |||||
Related-party accruals | 1,155,200 | 1,146,400 | |||||||
Valuation allowance | (5,245,600 | ) | (5,030,700 | ) | |||||
$ | - | $ | - | ||||||
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income for the years ended December 31, 2014 and 2013 due to the following: | ||||||||
2014 | 2013 | ||||||||
Income tax benefit based on U.S. statutory rate of 34% | $ | (659,700 | ) | $ | (454,600 | ) | |||
Stock issued for expenses | 154,400 | 52,700 | |||||||
Other | 290,400 | 439,700 | |||||||
Change in valuation allowance | 214,900 | (37,800 | ) | ||||||
$ | - | $ | - |
NOTE_2_PROPERTY_AND_EQUIPMENT_
NOTE 2 - PROPERTY AND EQUIPMENT (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Property, Plant and Equipment [Abstract] | |||||||||
Property, Plant and Equipment [Table Text Block] | Property and equipment consist of the following as of December 31, 2014 and 2013: | ||||||||
2014 | 2013 | ||||||||
Computers and software | $ | 2,938 | $ | 2,938 | |||||
Furniture | 2,075 | 2,075 | |||||||
5,013 | 5,013 | ||||||||
Accumulated depreciation | (4,183 | ) | (3,397 | ) | |||||
Property and equipment, net | $ | 830 | $ | 1,616 |
NOTE_3_TRADEMARK_AND_PATENTS_T
NOTE 3 - TRADEMARK AND PATENTS (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Disclosure Text Block [Abstract] | |||||||||
Schedule of Finite-Lived Intangible Assets [Table Text Block] | Trademark and patents consist of the following as of December 31, 2014 and 2013: | ||||||||
2014 | 2013 | ||||||||
Patent costs | $ | 362,956 | $ | 325,964 | |||||
Trademark | 770 | 770 | |||||||
363,726 | 326,734 | ||||||||
Accumulated amortization | (155,653 | ) | (107,171 | ) | |||||
Trademark and patents, net | $ | 208,073 | $ | 219,563 |
NOTE_4_ACCRUED_EXPENSES_AND_AC1
NOTE 4 - ACCRUED EXPENSES AND ACCRUED EXPENSES - RELATED PARTIES (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Payables and Accruals [Abstract] | |||||||||
Schedule of Accrued Liabilities [Table Text Block] | Accrued expenses and accrued expenses – related parties consist of the following as of December 31, 2014 and 2013: | ||||||||
2014 | 2013 | ||||||||
Accrued payroll and consulting – related parties | $ | 1,812,106 | $ | 1,812,106 | |||||
Accrued interest | 502,269 | 478,613 | |||||||
Accrued payroll taxes – related parties | 116,553 | 116,553 | |||||||
Other accruals | 14,165 | 43,566 | |||||||
Total | $ | 2,445,093 | $ | 2,450,838 |
NOTE_7_COMMON_STOCK_OPTIONS_Ta
NOTE 7 - COMMON STOCK OPTIONS (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Disclosure Text Block Supplement [Abstract] | |||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | The Company estimated the fair value of the stock options at the date of the grant, based on the following weighted average assumptions: | ||||||||
Risk-free interest rate | 1.5 | % | to | 1.69 | % | ||||
Expected life | 5 years | ||||||||
Expected volatility | 135.74 | % | to | 136.44 | % | ||||
Dividend yield | 0 | % | |||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | A summary of the status of the Company’s outstanding options as of December 31, 2014 and changes during the year then ended is presented below: | ||||||||
Shares | Weighted Average | ||||||||
Exercise Price | |||||||||
Outstanding, January 1, 2014 | 15,150,000 | $ | 0.19 | ||||||
Granted | 5,915,000 | 0.14 | |||||||
Expired/Canceled | (2,500,000 | ) | 0.1 | ||||||
Outstanding, December 31, 2014 | 18,565,000 | 0.18 | |||||||
Exercisable | 14,600,000 | 0.2 |
NOTE_9_NOTES_PAYABLE_Tables
NOTE 9 - NOTES PAYABLE (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2014 | |||||||||
Debt Disclosure [Abstract] | |||||||||
Schedule of Debt [Table Text Block] | Notes payable consist of the following as of December 31, 2014 and 2013: | ||||||||
2014 | 2013 | ||||||||
Unsecured notes payable to former directors and a family member of a former director, due at various dates in 1995, 1996 and 1997 (principal and accrued interest as of December 31, 2014), interest at 8% per annum. The Company has the right to repay the loans with restricted stock at $0.10 per share if alternative financings do not occur. These notes payable are in default. | $ | 182,676 | $ | 182,676 | |||||
Unsecured notes payable to 10 stockholders, due on demand, interest at 10% per annum (principal and accrued interest, as of December 31, 2014). The Company is obligated to accept the principal rate at face value plus accrued interest as partial payment for shares the lenders may purchase from the Company upon exercise of the lenders’ option to acquire shares from the Company. | 60,815 | 60,815 | |||||||
Unsecured notes payable to directors totaling $28,000 and a note payable to a third party in the amount of $9,000, due on April 22, 1995 (principal and accrued interest as of December 31, 2014), interest at 8% per annum. Each lender has the right to convert any portion of the principal and interest into common stock at a price per share equal to the price per share under a prior private placement transaction. These notes payable are in default. | 37,000 | 37,000 | |||||||
Unsecured notes payable to a financing company, payable in nine monthly installments, interest ranging from 4.00% to 5.68% per annum, mature in April, July and November 2015. | 17,750 | 15,005 | |||||||
Total notes payable (all current) | $ | 298,241 | $ | 295,496 |
NOTE_1_ORGANIZATION_AND_SUMMAR2
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Operating Loss Carryforwards | ($10,267,000) | |
Income Tax Expense (Benefit) | 0 | 0 |
Liability for Uncertain Tax Positions, Current | $0 | $0 |
Computer Equipment [Member] | ||
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Property, Plant and Equipment, Useful Life | 3 years | |
Office Equipment [Member] | ||
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Property, Plant and Equipment, Useful Life | 5 years | |
Trademarks [Member] | ||
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Finite-Lived Intangible Asset, Useful Life | 7 years | |
Minimum [Member] | ||
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Operating Loss Carryforwards, Expiration Date 1 | 2015 | |
Maximum [Member] | ||
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||
Operating Loss Carryforwards, Expiration Date 1 | 2033 |
NOTE_1_ORGANIZATION_AND_SUMMAR3
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Earnings Per Share, Basic and Diluted (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Schedule of Earnings Per Share, Basic and Diluted [Abstract] | ||
Numerator (net loss) | ($1,940,440) | ($1,336,992) |
Denominator (weighted average number of common shares outstanding) | 335,658,604 | 307,880,349 |
Basic and diluted net loss per common share | ($0.01) | $0 |
NOTE_1_ORGANIZATION_AND_SUMMAR4
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Deferred Tax Assets and Liabilities (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Schedule of Deferred Tax Assets and Liabilities [Abstract] | ||
Net operating loss carryforwards | $4,090,400 | $3,884,300 |
Related-party accruals | 1,155,200 | 1,146,400 |
Valuation allowance | -5,245,600 | -5,030,700 |
$0 | $0 |
NOTE_1_ORGANIZATION_AND_SUMMAR5
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Effective Income Tax Rate Reconciliation (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Schedule of Effective Income Tax Rate Reconciliation [Abstract] | ||
Income tax benefit based on U.S. statutory rate of 34% | ($659,700) | ($454,600) |
Stock issued for expenses | 154,400 | 52,700 |
Other | 290,400 | 439,700 |
Change in valuation allowance | 214,900 | -37,800 |
$0 | $0 |
NOTE_1_ORGANIZATION_AND_SUMMAR6
NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Effective Income Tax Rate Reconciliation (Parentheticals) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Schedule of Effective Income Tax Rate Reconciliation [Abstract] | ||
Income tax benefit statutory rate | 34.00% | 34.00% |
NOTE_2_PROPERTY_AND_EQUIPMENT_1
NOTE 2 - PROPERTY AND EQUIPMENT (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Property, Plant and Equipment [Abstract] | ||
Depreciation | $787 | $4,203 |
NOTE_2_PROPERTY_AND_EQUIPMENT_2
NOTE 2 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Property, Plant and Equipment [Line Items] | ||
Property and Equipment, Gross | $5,013 | $5,013 |
Accumulated depreciation | -4,183 | -3,397 |
Property and equipment, net | 830 | 1,616 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment, Gross | 2,938 | 2,938 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and Equipment, Gross | $2,075 | $2,075 |
NOTE_3_TRADEMARK_AND_PATENTS_D
NOTE 3 - TRADEMARK AND PATENTS (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Disclosure Text Block [Abstract] | ||
Amortization of Intangible Assets | $48,483 | $43,730 |
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months | 51,310 | |
Finite-Lived Intangible Assets, Amortization Expense, Year Two | 51,109 | |
Finite-Lived Intangible Assets, Amortization Expense, Year Three | 43,860 | |
Finite-Lived Intangible Assets, Amortization Expense, Year Four | 31,280 | |
Finite-Lived Intangible Assets, Amortization Expense, Year Five | 17,615 | |
Finite-Lived Intangible Assets, Amortization Expense, after Year Five | $12,899 |
NOTE_3_TRADEMARK_AND_PATENTS_D1
NOTE 3 - TRADEMARK AND PATENTS (Details) - Schedule of Finite-Lived Intangible Assets (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Finite-Lived Intangible Assets [Line Items] | ||
Intangible Assets, Gross | $363,726 | $326,734 |
Accumulated amortization | -155,653 | -107,171 |
Trademark and patents, net | 208,073 | 219,563 |
Patents [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Intangible Assets, Gross | 362,956 | 325,964 |
Trademarks [Member] | ||
Finite-Lived Intangible Assets [Line Items] | ||
Intangible Assets, Gross | $770 | $770 |
NOTE_4_ACCRUED_EXPENSES_AND_AC2
NOTE 4 - ACCRUED EXPENSES AND ACCRUED EXPENSES - RELATED PARTIES (Details) - Schedule of Accrued Liabilities (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Schedule of Accrued Liabilities [Abstract] | ||
Accrued payroll and consulting b related parties | $1,812,106 | $1,812,106 |
Accrued interest | 502,269 | 478,613 |
Accrued payroll taxes b related parties | 116,553 | 116,553 |
Other accruals | 14,165 | 43,566 |
Total | $2,445,093 | $2,450,838 |
NOTE_5_COMMITMENTS_AND_CONTING1
NOTE 5 - COMMITMENTS AND CONTINGENCIES (Details) | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2002 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2001 | Dec. 31, 2014 | Dec. 31, 2014 | Dec. 31, 2014 | Dec. 31, 2014 |
USD ($) | USD ($) | Default Judgement [Member] | Default Judgement [Member] | Default Judgement [Member] | Litigation Fees [Member] | Litigation Fees [Member] | Rakas Litigation [Member] | Certified Laboratory Space [Member] | Second Laboratory for Full Scale Room Testing [Member] | Full Scale Room Testing [Member] | Corporate Offices [Member] | |
Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | Rakas Litigation [Member] | Settlement Amount, September 2001 [Member] | CAD | CAD | CAD | USD ($) | |||
Settlement Amount, January 2002 [Member] | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |||||||
USD ($) | ||||||||||||
NOTE 5 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items] | ||||||||||||
Litigation Settlement, Amount | $25,000 | |||||||||||
Loss Contingency, Damages Sought, Value | 143,000 | |||||||||||
Accounts Payable, Current | 470,147 | 477,563 | 143,000 | 143,000 | 21,308 | 21,308 | ||||||
Accounts Payable, Other, Current | 224,852 | 224,852 | ||||||||||
Operating Leases, Rent Expense, Minimum Rentals | 1,375 | 1,375 | 475 | $2,300 |
NOTE_6_EQUITY_TRANSACTIONS_Det
NOTE 6 - EQUITY TRANSACTIONS (Details) (USD $) | 12 Months Ended | 3 Months Ended | 1 Months Ended | 2 Months Ended | 3 Months Ended | ||||||||
Dec. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2014 | Mar. 31, 2014 | Dec. 31, 2014 | Nov. 30, 2014 | Sep. 30, 2014 | Dec. 31, 2013 | Oct. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | 31-May-13 | Mar. 31, 2013 | |
NOTE 6 - EQUITY TRANSACTIONS (Details) [Line Items] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 23,978,572 | ||||||||||||
Proceeds from Issuance of Common Stock (in Dollars) | $1,604,250 | $1,413,250 | |||||||||||
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||
Preferred Stock, Shares Authorized | 50,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | |||||||||
Preferred Stock, Shares Issued | 0 | 0 | 0 | 0 | |||||||||
Common Stock, Shares Authorized | 395,000,000 | 395,000,000 | 395,000,000 | 395,000,000 | |||||||||
Common Stock, Par or Stated Value Per Share (in Dollars per share) | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||
Stock Issued January, February and March 2014 [Member] | Restricted Stock [Member] | |||||||||||||
NOTE 6 - EQUITY TRANSACTIONS (Details) [Line Items] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 9,000,000 | ||||||||||||
Number of Investors | 5 | ||||||||||||
Proceeds from Issuance or Sale of Equity (in Dollars) | 450,000 | ||||||||||||
Sale of Stock, Price Per Share (in Dollars per share) | $0.05 | $0.05 | |||||||||||
Stock Issued March 2014 [Member] | Restricted Stock [Member] | |||||||||||||
NOTE 6 - EQUITY TRANSACTIONS (Details) [Line Items] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 7,050,000 | ||||||||||||
Number of Investors | 16 | ||||||||||||
Proceeds from Issuance or Sale of Equity (in Dollars) | 599,250 | ||||||||||||
Sale of Stock, Price Per Share (in Dollars per share) | $0.09 | $0.09 | |||||||||||
Restricted Stock [Member] | |||||||||||||
NOTE 6 - EQUITY TRANSACTIONS (Details) [Line Items] | |||||||||||||
Stock Issued During Period, Shares, New Issues | 2,550,000 | 2,907,143 | 2,471,429 | 4,442,857 | 1,950,000 | 5,000,000 | 5,863,636 | 3,794,444 | 12,233,332 | ||||
Number of Investors | 5 | 5 | 6 | 5 | 8 | 12 | 6 | 12 | |||||
Proceeds from Issuance or Sale of Equity (in Dollars) | 178,500 | 203,500 | 155,500 | 97,500 | 300,000 | 322,500 | 170,750 | 367,000 | |||||
Shares Issued, Price Per Share (in Dollars per share) | $0.04 | $0.04 | $0.05 | $0.06 | $0.06 | $0.05 | $0.03 | ||||||
Sale of Stock, Price Per Share (in Dollars per share) | $0.07 | $0.07 | $0.07 | $0.07 | |||||||||
Proceeds from Issuance of Common Stock (in Dollars) | $173,000 |
NOTE_7_COMMON_STOCK_OPTIONS_De
NOTE 7 - COMMON STOCK OPTIONS (Details) (USD $) | 12 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 9 Months Ended | |||||||||
Dec. 31, 2014 | Dec. 31, 2013 | Dec. 31, 2012 | Feb. 26, 2014 | Apr. 30, 2014 | Aug. 15, 2014 | Oct. 07, 2014 | Aug. 26, 2009 | Sep. 30, 2012 | 31-May-12 | Aug. 31, 2013 | 6-May-14 | Dec. 04, 2014 | Sep. 30, 2014 | |
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 5,915,000 | |||||||||||||
Share-based Compensation (in Dollars) | $453,987 | $131,866 | $453,987 | |||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | 121,949 | |||||||||||||
Director [Member] | Employee Stock Option [Member] | February 2014 [Member] | Share-based Compensation Award, Tranche One [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 1,000,000 | |||||||||||||
Director [Member] | Employee Stock Option [Member] | February 2014 [Member] | Share-based Compensation Award, Tranche Two [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | vest upon the successful achievement of certain milestones | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 1,000,000 | |||||||||||||
Director [Member] | Employee Stock Option [Member] | February 2014 [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 2,000,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | 0.1095 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation (in Dollars) | 80,076 | |||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | 16,016 | |||||||||||||
Director [Member] | Employee Stock Option [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Number of directors issued options | 4 | |||||||||||||
Director [Member] | Employee Stock Option [Member] | August 15, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,000,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $0.13 | |||||||||||||
Share-based Compensation (in Dollars) | 114,069 | |||||||||||||
Director [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 250,000 | |||||||||||||
Director [Member] | October 7, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,000,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $0.16 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | These options will vest on October 7, 2015. Unvested options vest immediately in the event of a change in control of the Company. | |||||||||||||
Share-based Compensation (in Dollars) | 35,044 | |||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | 105,133 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $140,178 | |||||||||||||
Director Two [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 250,000 | |||||||||||||
Director Three [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 250,000 | |||||||||||||
Director Four [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 250,000 | |||||||||||||
Consultant Two [Member] | Non-Employee Stock Option [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 100,000 | |||||||||||||
Consultant Three [Member] | Non-Employee Stock Option [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 75,000 | |||||||||||||
Employee [Member] | Non-Employee Stock Option [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 75,000 | |||||||||||||
Consultant [Member] | Non-Employee Stock Option [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 100,000 | |||||||||||||
Non-Employee Stock Option [Member] | August 26, 2009 [Member] | Share-based Compensation Award, Tranche Three [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | (i) options for 500,000 shares vested immediately on the date of grant, (ii) options for 500,000 shares vested in September 2012, the date certified by the Company as the date its hospital disinfection program completed its beta-testing, and (iii) the remaining options for 500,000 shares were to vest on the date certified by the Company as the date that its disinfection process has been commercialized and a minimum of 50 units or devices have been sold to third parties. | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 500,000 | |||||||||||||
Non-Employee Stock Option [Member] | August 26, 2009 [Member] | Share-based Compensation Award, Tranche One [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 500,000 | |||||||||||||
Non-Employee Stock Option [Member] | August 26, 2009 [Member] | Share-based Compensation Award, Tranche Two [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 500,000 | |||||||||||||
Non-Employee Stock Option [Member] | August 26, 2009 [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,500,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | 0.1 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Non-Employee Stock Option [Member] | May 2012 [Member] | Options Granted for Distribution Channel Related Services [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,000,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $0.17 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 550,000 | |||||||||||||
Share-based Compensation (in Dollars) | 69,300 | |||||||||||||
Non-Employee Stock Option [Member] | May 2012 [Member] | Options Granted for Medical Consulting Support Services [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,000,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $0.17 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation (in Dollars) | 49,322 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | $149,460 | |||||||||||||
Non-Employee Stock Option [Member] | August 2013 [Member] | Share-based Compensation Award, Tranche One [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 50,000 | |||||||||||||
Non-Employee Stock Option [Member] | August 2013 [Member] | Share-based Compensation Award, Tranche Two [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | vesting upon the achievement of certain milestones | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | 200,000 | |||||||||||||
Non-Employee Stock Option [Member] | August 2013 [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 250,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | 0.1 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation (in Dollars) | 4,415 | |||||||||||||
Non-Employee Stock Option [Member] | February 2014 [Member] | Share-based Compensation Award, Tranche One [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 200,000 | |||||||||||||
Non-Employee Stock Option [Member] | February 2014 [Member] | Share-based Compensation Award, Tranche Two [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 50,000 | |||||||||||||
Non-Employee Stock Option [Member] | February 2014 [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 250,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | 0.1095 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation (in Dollars) | 23,223 | |||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | 800 | |||||||||||||
Number of consultants and service providers issued options | 6 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share) | 24,023 | |||||||||||||
Non-Employee Stock Option [Member] | April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Number of consultants and service providers issued options | 2 | |||||||||||||
Non-Employee Stock Option [Member] | May 6, 2014 [Member] | Share-based Compensation Award, Tranche One [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 50,000 | |||||||||||||
Non-Employee Stock Option [Member] | May 6, 2014 [Member] | Share-based Compensation Award, Tranche Two [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | vest when certain required milestones are achieved | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 50,000 | |||||||||||||
Non-Employee Stock Option [Member] | May 6, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 100,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | 0.19 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation (in Dollars) | 8,342 | |||||||||||||
Non-Employee Stock Option [Member] | August 15, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 75,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $0.13 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Non-Employee Stock Option [Member] | December 4, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 140,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | $0.11 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | The shares will vest when certain required milestones are achieved. | |||||||||||||
Number of consultants and service providers issued options | 4 | |||||||||||||
Employee Stock Option [Member] | August 2013 [Member] | 2012 Equity Incentive Award Plan [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 100,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | 0.1 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation (in Dollars) | 8,829 | |||||||||||||
April 30, 2014 [Member] | 2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,350,000 | |||||||||||||
Share-based Compensation by Share-based Payment Award, Options, Exercise Price of Options (in Dollars per share) | 0.163 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years | |||||||||||||
Share-based Compensation (in Dollars) | $193,234 | |||||||||||||
Minimum [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 50 months | |||||||||||||
Maximum [Member] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 58 months | |||||||||||||
2014 Equity Compensation Plan [Mmember] | ||||||||||||||
NOTE 7 - COMMON STOCK OPTIONS (Details) [Line Items] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 6,000,000 |
NOTE_7_COMMON_STOCK_OPTIONS_De1
NOTE 7 - COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options | 12 Months Ended |
Dec. 31, 2014 | |
Minimum [Member] | |
NOTE 7 - COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items] | |
Risk-free interest rate | 1.50% |
Expected volatility | 135.74% |
Maximum [Member] | |
NOTE 7 - COMMON STOCK OPTIONS (Details) - Schedule of Fair Value Assumptions of Stock Options [Line Items] | |
Risk-free interest rate | 1.69% |
Expected life | 5 years |
Expected volatility | 136.44% |
Dividend yield | 0.00% |
NOTE_7_COMMON_STOCK_OPTIONS_De2
NOTE 7 - COMMON STOCK OPTIONS (Details) - Schedule of Share-Based Compensation, Stock Options, Activity (USD $) | 12 Months Ended |
Dec. 31, 2014 | |
Schedule of Share-Based Compensation, Stock Options, Activity [Abstract] | |
Outstanding, January 1, 2014 | 15,150,000 |
Outstanding, January 1, 2014 | $0.19 |
Granted | 5,915,000 |
Granted | $0.14 |
Expired/Canceled | -2,500,000 |
Expired/Canceled | $0.10 |
Outstanding, December 31, 2014 | 18,565,000 |
Outstanding, December 31, 2014 | $0.18 |
Exercisable | 14,600,000 |
Exercisable | $0.20 |
NOTE_8_ACCOUNTS_PAYABLE_RELATE1
NOTE 8 - ACCOUNTS PAYABLE - RELATED PARTIES (Details) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Related Party Transactions [Abstract] | ||
Accounts Payable, Related Parties, Current | $233,109 | $234,677 |
NOTE_9_NOTES_PAYABLE_Details_S
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items] | ||
Note Payable | $298,241 | $295,496 |
Unsecured Note 1 [Member] | Loans Payable [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items] | ||
Note Payable | 182,676 | 182,676 |
Unsecured Note 2 [Member] | Loans Payable [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items] | ||
Note Payable | 60,815 | 60,815 |
Unsecured Note 3 [Member] | Loans Payable [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items] | ||
Note Payable | 37,000 | 37,000 |
Unsecured Note 4 [Member] | Loans Payable [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt [Line Items] | ||
Note Payable | $17,750 | $15,005 |
NOTE_9_NOTES_PAYABLE_Details_S1
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) (Loans Payable [Member], USD $) | 12 Months Ended | |
Dec. 31, 2014 | Dec. 31, 2013 | |
Director [Member] | Unsecured Note 3 [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Note amount | 28,000 | 28,000 |
Unsecured Note 1 [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Due | Various dates in 1995, 1996 and 1997 | Various dates in 1995, 1996 and 1997 |
Interest | 8.00% | 8.00% |
Note Repayment Term | The Company has the right to repay the loans with restricted stock at $0.10 per share if alternative financings do not occur. | The Company has the right to repay the loans with restricted stock at $0.10 per share if alternative financings do not occur. |
Unsecured Note 2 [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Interest | 10.00% | 10.00% |
Stockholders | 10 | 10 |
Unsecured Note 3 [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Interest | 8.00% | 8.00% |
Note amount | 9,000 | 9,000 |
Due | 22-Apr-95 | 22-Apr-95 |
Note Conversion Terms | Each lender has the right to convert any portion of the principal and interest into common stock at a price per share equal to the price per share under a prior private placement transaction. | Each lender has the right to convert any portion of the principal and interest into common stock at a price per share equal to the price per share under a prior private placement transaction. |
Note Default | These notes payable are in default. | These notes payable are in default. |
Unsecured Note 4 [Member] | Minimum [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Interest | 4.00% | 4.00% |
Unsecured Note 4 [Member] | Maximum [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Interest | 5.68% | 5.68% |
Unsecured Note 4 [Member] | ||
NOTE 9 - NOTES PAYABLE (Details) - Schedule of Debt (Parentheticals) [Line Items] | ||
Due | April, July and November 2015 | April, July and November 2015 |
Notes, payable in | Nine monthly installments | Nine monthly installments |
NOTE_10_GOING_CONCERN_Details
NOTE 10 - GOING CONCERN (Details) (USD $) | 12 Months Ended | 1 Months Ended | 2 Months Ended | 3 Months Ended | |||||||||
Dec. 31, 2014 | Dec. 31, 2013 | Feb. 13, 2015 | Dec. 31, 2014 | Nov. 30, 2014 | Sep. 30, 2014 | Dec. 31, 2013 | Oct. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | 31-May-13 | Mar. 31, 2013 | Dec. 31, 2012 | |
NOTE 10 - GOING CONCERN (Details) [Line Items] | |||||||||||||
Retained Earnings (Accumulated Deficit) | ($33,362,424) | ($31,421,984) | ($33,362,424) | ($31,421,984) | |||||||||
Working capital (deficit) | -3,235,007 | -3,235,007 | |||||||||||
Stockholders' Equity Attributable to Parent | -3,021,832 | -3,107,800 | -3,021,832 | -3,107,800 | -3,314,099 | ||||||||
Going Concern Note | The Company believes that it will need approximately $1,500,000 during the next 12 months for continued production manufacturing and related activities, research, development, marketing activities, as well as for general corporate purposes. | ||||||||||||
Proceeds from Issuance of Common Stock | 1,604,250 | 1,413,250 | |||||||||||
Stock Issued During Period, Shares, New Issues (in Shares) | 23,978,572 | ||||||||||||
Common Stock [Member] | Minimum [Member] | |||||||||||||
NOTE 10 - GOING CONCERN (Details) [Line Items] | |||||||||||||
Sale of Stock, Price Per Share (in Dollars per share) | $0.05 | $0.03 | $0.05 | $0.03 | |||||||||
Common Stock [Member] | Maximum [Member] | |||||||||||||
NOTE 10 - GOING CONCERN (Details) [Line Items] | |||||||||||||
Sale of Stock, Price Per Share (in Dollars per share) | $0.09 | $0.06 | $0.09 | $0.06 | |||||||||
Common Stock [Member] | |||||||||||||
NOTE 10 - GOING CONCERN (Details) [Line Items] | |||||||||||||
Stockholders' Equity Attributable to Parent | 346,034 | 322,055 | 346,034 | 322,055 | 288,771 | ||||||||
Stock Issued During Period, Shares, New Issues (in Shares) | 23,978,572 | 33,284,269 | |||||||||||
Restricted Stock [Member] | Subsequent Event [Member] | |||||||||||||
NOTE 10 - GOING CONCERN (Details) [Line Items] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in Shares) | 300,000 | ||||||||||||
Sale of Stock, Price Per Share (in Dollars per share) | $0.07 | ||||||||||||
Proceeds from Issuance or Sale of Equity | 21,000 | ||||||||||||
Restricted Stock [Member] | |||||||||||||
NOTE 10 - GOING CONCERN (Details) [Line Items] | |||||||||||||
Proceeds from Issuance of Common Stock | 173,000 | ||||||||||||
Stock Issued During Period, Shares, New Issues (in Shares) | 2,550,000 | 2,907,143 | 2,471,429 | 4,442,857 | 1,950,000 | 5,000,000 | 5,863,636 | 3,794,444 | 12,233,332 | ||||
Sale of Stock, Price Per Share (in Dollars per share) | $0.07 | $0.07 | $0.07 | $0.07 | |||||||||
Proceeds from Issuance or Sale of Equity | $178,500 | $203,500 | $155,500 | $97,500 | $300,000 | $322,500 | $170,750 | $367,000 |
NOTE_11_CUSTOMER_DEPOSITS_Deta
NOTE 11 - CUSTOMER DEPOSITS (Details) (USD $) | Dec. 31, 2014 | Dec. 31, 2013 |
Deferred Revenue Disclosure [Abstract] | ||
Customer Deposits, Current | $30,000 | $30,000 |
NOTE_12_SUBSEQUENT_EVENTS_Deta
NOTE 12 - SUBSEQUENT EVENTS (Details) (USD $) | 12 Months Ended | 1 Months Ended | 2 Months Ended | 3 Months Ended | |||||||
Dec. 31, 2014 | Feb. 13, 2015 | Dec. 31, 2014 | Nov. 30, 2014 | Sep. 30, 2014 | Dec. 31, 2013 | Oct. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | 31-May-13 | Mar. 31, 2013 | |
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||
Stock Issued During Period, Shares, New Issues | 23,978,572 | ||||||||||
Restricted Stock [Member] | Subsequent Event [Member] | January and February 2015 [Member] | |||||||||||
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||
Stock Issued During Period, Shares, New Issues | 300,000 | ||||||||||
Proceeds from Issuance or Sale of Equity | $21,000 | ||||||||||
Sale of Stock, Price Per Share | $0.07 | ||||||||||
Restricted Stock [Member] | Subsequent Event [Member] | |||||||||||
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||
Stock Issued During Period, Shares, New Issues | 300,000 | ||||||||||
Proceeds from Issuance or Sale of Equity | 21,000 | ||||||||||
Sale of Stock, Price Per Share | $0.07 | ||||||||||
Restricted Stock [Member] | |||||||||||
NOTE 12 - SUBSEQUENT EVENTS (Details) [Line Items] | |||||||||||
Stock Issued During Period, Shares, New Issues | 2,550,000 | 2,907,143 | 2,471,429 | 4,442,857 | 1,950,000 | 5,000,000 | 5,863,636 | 3,794,444 | 12,233,332 | ||
Proceeds from Issuance or Sale of Equity | $178,500 | $203,500 | $155,500 | $97,500 | $300,000 | $322,500 | $170,750 | $367,000 | |||
Sale of Stock, Price Per Share | 0.07 | $0.07 | $0.07 | $0.07 |